Novo Nordisk A/S Common Stock (NVO)

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE).

The weight loss drug market is on track to reach almost $100 billion.

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

These stocks have been struggling over the past year, but their growth days are far from over.

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Lilly's weight loss drugs have been delivering blockbuster revenue.

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

And he may be right.

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Eli Lilly has more to offer than some investors realize.

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

The weight loss drug market may reach almost $100 billion in a few years.

High hopes for a freshly approved drug might not be realized, if early data is any indication.

A rival company's trial results had a negative impact on Agios' stock this week.

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met